MicroRNA‐483 Amelioration of Experimental Pulmonary Hypertension
Jin Zhang,Yangyang He,Xiaosong Yan,Shanshan Chen,Ming He,Yuyang Lei,Jiao Zhang,Brendan Gongol,Mingxia Gu,Yifei Miao,Liang Bai,Xiaopei Cui,Xiaojian Wang,Yixin Zhang,Fenling Fan,Zhao Li,Yuan Shen,Chih-Hung Chou,Hsien-Da Huang,Atul Malhotra,Marlene Rabinovitch,Zhi-Cheng Jing,John Y-J Shyy
DOI: https://doi.org/10.15252/emmm.201911303
2020-01-01
EMBO Molecular Medicine
Abstract:Endothelial dysfunction is critically involved in the pathogenesis of pulmonary arterial hypertension (PAH) and that exogenously administered microRNA may be of therapeutic benefit. Lower levels of miR-483 were found in serum from patients with idiopathic pulmonary arterial hypertension (IPAH), particularly those with more severe disease. RNA-seq and bioinformatics analyses showed that miR-483 targets several PAH-related genes, including transforming growth factor-beta (TGF-beta), TGF-beta receptor 2 (TGFBR2), beta-catenin, connective tissue growth factor (CTGF), interleukin-1 beta (IL-1 beta), and endothelin-1 (ET-1). Overexpression of miR-483 in ECs inhibited inflammatory and fibrogenic responses, revealed by the decreased expression of TGF-beta, TGFBR2, beta-catenin, CTGF, IL-1 beta, and ET-1. In contrast, inhibition of miR-483 increased these genes in ECs. Rats with EC-specific miR-483 overexpression exhibited ameliorated pulmonary hypertension (PH) and reduced right ventricular hypertrophy on challenge with monocrotaline (MCT) or Sugen + hypoxia. A reversal effect was observed in rats that received MCT with inhaled lentivirus overexpressing miR-483. These results indicate that PAH is associated with a reduced level of miR-483 and that miR-483 might reduce experimental PH by inhibition of multiple adverse responses.